Iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis and the quality of life: A new therapeutic protocol

Rheumatology

Volumn 45, Issue 8, 2006, Pages 999-1004

  Milio, Glauco ^a,b   Corrado, E ^a   Genova, C ^a   Amato, C ^a   Raimondi, F ^a   Almasio, P L ^a   Novo, S ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b NONE   (Italy)

Author keywords

Iloprost; Quality of life; Raynaud's phenomenon; Systemic sclerosis

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ILOPROST; VASODILATOR AGENT;

ADULT; ARTICLE; CLINICAL FEATURE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG INFUSION; FEMALE; FREQUENCY ANALYSIS; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RAYNAUD PHENOMENON; SHORT FORM 36; SYSTEMIC SCLEROSIS; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; ILOPROST; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUALITY OF LIFE; RAYNAUD DISEASE; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 33747839186     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kel038     Document Type: Article

References (32)

1. Black CM. Systemic sclerosis: 'state of the art' 1995. Scand J Rheumatol 1995;24:194-6.
2. Le Roy EC. Systemic sclerosis: A vascular perspective. Rheum Dis Clin North Am 1996;22:675-94.
3. Le Roy EC, Black C, Fleischmajer R et al. Scleroderma (systemic sclerosis): Classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5.
4. Silver RM. Clinical aspects of systemic sclerosis (scleroderma). Ann Rheum Dis 1991;50:854-61.
5. Generini S, Matucci Cerinic M. Raynaud's phenomenon and vascular disease in systemic sclerosis. Adv Exp Med Biol 1999;455:93-100.
6. Generini S, Kahaleh BM, Matucci Cerinic M, Pignone A, Lombardi A, Ohtsuka T. Raynaud's phenomenon and systemic sclerosis. Ann Ital Med Int 1996;11:125-31.
7. Wigley FM, Flavahan NA. Raynaud's phenomenon. Rheum Dis Clin North Am 1996;22:765-81.
8. Feghali CA, Bost KL, Boulware DW, Levy LS. Mechanisms of pathogenesis in scleroderma: Overproduction of interleukin 6 by fibroblasts cultured from affected skin sites of patients with scleroderma. J Rheumatol 1992;19:1207-11.
9. Furst DE. The endothelium in the pathogenesis of systemic sclerosis: Is it primary or secondary? J Malad Vasc 1999;24:95-8.
10. Kahaleh MB. Vascular disease in scleroderma: Endothelial cell injury hypothesis. Rheum Dis Clin N Am 1990;16: 57.
11. Pearson JD. The endothelium: Its role in scleroderma. Ann Rheum Dis 1991;50:866-71.
12. Kahaleh BM. Lymphocyte interaction with the vascular endothelium in scleroderma. Clin Dermatol 1994;12:175-81.
13. Lau CS, O'Dowd A, Belch JJF. White cell activation in the Raynaud's phenomenon of systemic sclerosis and vibration induced white finger syndrome. Ann Rheum Dis 1992;51:249-52.
14. Krause W, Krais T. Pharmacokinetics and pharmacodynamics of the prostacyclin analogue iloprost in man. Eur J Clin Pharmacol 1985;30:61-8.
15. Arpaia G, Cimminiello C, Sardina M et al. Microcirculatory effects of iloprost in patients with suspected secondary Raynaud's phenomenon. Vasc Surg 1995;29:37-42.
16. Grushwitz MS, Hornstein OP, Von Den Driesch P. Correlation of soluble adhesion molecules in the peripheral blood of scleroderma patients with their in situ expression and with disease activity. Arthritis Rheum 1995;38:184-9.
17. Mazzone A, Mazzucchelli I, Fossati G et al. Iloprost effects on phagocytes in patients suffering from ischemic disease: In vivo evidence for down-regulation of alpha-M-beta2-integrin. Eur J Clin Invest 1996;26:860-6.
18. Bettoni L, Geri A, Airo P et al. Systemic sclerosis therapy with iloprost: A prospective observational study of 30 patients treated for a median of 3 years. Clin Rheumatol 2002;21:244-50.
19. Kyle MV, Belcher G, Hazleman BL. Placebo controlled study showing therapeutic benefit of iloprost in the treatment of Raynaud's phenomenon. J Rheumatol 1992;19:1403-6.
20. Rademaker M, Cooke ED, Almond NE et al. Comparison of intravenous infusion of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: A double blind randomised study. Br Med J 1989;298:561-4.
21. Scorza R, Caronni M, Mascagni B et al. Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon. A randomized controlled study. Clin Exp Rheumatol 2001; 19:503-8.
22. Wigley FM, Wise RA, Seibold JR et al. Intravenous iloprost infusion in patients with Raynaud's phenomenon secondary to systemic sclerosis: A multicenter, placebo-controlled, double-blind study. Ann Intern Med 1994;120:199-206.
23. Cerù S, Pancera P, Sansone S et al. Effects of five-day versus one-day infusion of iloprost on the peripheral microcirculation in patients with systemic sclerosis. Clin Exp Rheumatol 1997; 15:381-5.
24. Torley HI, Madhok R, Capell HA. A double blind, randomised, multicentre comparison of two doses of intravenous iloprost in the treatment of Raynaud's phenomenon secondary to connective tissue disease. Ann Rheum Dis 1991;50:800-4.
25. Moher D, Schulz KF, Altman DG, for the CONSORT group. The CONSORT statement: Revised recommendation for improving the quality of reports of parallel group randomized trials. JAMA 2001;285:1987-91.
26. Clements PJ. Measuring disease activity and severity in scleroderma. Curr Opin Rheumatol 1995;7:517-21.
27. Kempen GI, Ormel J, Brilman EI, Relyveld J. Adaptive responses among Dutch elderly: The impact of eight chronic medical conditions on health-related quality of life. Am J Public Health 1997;87:38-44.
28. Stewart AL, Greenfield S, Hays RD et al. Functional status and well-being of patients with chronic conditions. Results from the Medical Outcomes Study. J Am Med Assoc 1989;262:907-13.
29. Lehmann EL. Nonparametrics: Statistical methods based on ranks. San Francisco, Holden-Day, 1975.
30. Cossutta R, Zeni S, Soldi A et al. Valutazione della qualità della vita in pazienti affetti da sclerosi sistemica mediante somministrazione del questionario SF-36. Reumatismo 2002;54:122-7.
31. Silman A, Akesson A, Newman J et al. Assessment of functional ability in patients with scleroderma: A proposed new disability assessment instrument. J Rheumatol 1998;25:79-83.
32. Ruof J, Bruhlmann P, Michel BA, Stucki G. Development and validation of a self-administered systemic sclerosis questionnaire (SySQ). Rheumatology 1999;38:535-42.